Biofrontera (B8FK) Stock Overview
A biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
B8FK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Biofrontera AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.36 |
| 52 Week High | €2.96 |
| 52 Week Low | €2.16 |
| Beta | -0.17 |
| 1 Month Change | -6.72% |
| 3 Month Change | -3.28% |
| 1 Year Change | -9.58% |
| 3 Year Change | -90.01% |
| 5 Year Change | -95.84% |
| Change since IPO | -99.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| B8FK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.3% | 3.3% | -0.9% |
| 1Y | -9.6% | 22.3% | -1.6% |
Return vs Industry: B8FK underperformed the German Pharmaceuticals industry which returned 24.1% over the past year.
Return vs Market: B8FK underperformed the German Market which returned 0.2% over the past year.
Price Volatility
| B8FK volatility | |
|---|---|
| B8FK Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: B8FK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: B8FK's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 74 | n/a | www.biofrontera.com |
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin.
Biofrontera AG Fundamentals Summary
| B8FK fundamental statistics | |
|---|---|
| Market cap | €14.34m |
| Earnings (TTM) | -€6.94m |
| Revenue (TTM) | €13.19m |
Is B8FK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B8FK income statement (TTM) | |
|---|---|
| Revenue | €13.19m |
| Cost of Revenue | €2.28m |
| Gross Profit | €10.91m |
| Other Expenses | €17.85m |
| Earnings | -€6.94m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 31, 2026
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 82.71% |
| Net Profit Margin | -52.64% |
| Debt/Equity Ratio | 0% |
How did B8FK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/15 12:59 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biofrontera AG is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Tsvetan Kintisheff | First Berlin Equity Research GmbH |
| Thomas Flaten | Lake Street Capital Markets, LLC |